Among adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with a 29% lower risk of dying from cardiovascular causes compared to taking a...
Mechanism
Synthesis from 1 study
Semaglutide helps the body manage blood sugar better, lowers blood pressure, and reduces excess fat. This takes the strain off the heart and blood vessels, making it less likely for someone with diabetes and kidney disease to die from heart problems.
Most probable mechanism
Semaglutide helps the body use insulin better, lowers blood sugar, reduces blood pressure, and decreases fat around the heart and blood vessels. This makes the heart work less hard and lowers the chance of heart failure or heart attacks.
Activation of GLP-1 receptors in pancreatic beta cells enhances glucose-dependent insulin secretion
Reduced hepatic glucose production lowers fasting and postprandial blood glucose levels
GLP-1 receptor activation in vascular endothelium and smooth muscle promotes vasodilation and lowers systemic blood pressure
Reduced adiposity and ectopic fat deposition in cardiac and perivascular tissues decreases mechanical and inflammatory strain on the cardiovascular system
Lowered glucose toxicity and reduced oxidative stress improve endothelial function and reduce atherosclerotic plaque vulnerability
Evidence from Studies
Supporting (1)
Community contributions welcome
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.